热门资讯> 正文

AVITA Medical任命Cary Vance为临时首席执行官

2025-10-17 14:09

AVITA Medical (NASDAQ: NASDAQ:RCEL) announced on Thursday that the board appointed Chairman of the Board Cary Vance as Interim CEO, effective immediately.
The board plans to engage an executive search firm to assist with selecting a permanent CEO.
The company expected initial revenue to be approximately $17M for Q3 ended September 30, 2025.
Following the company’s credit agreement with OrbiMed, the company has been granted a waiver for the third quarter 2025 trailing 12-month net revenue covenant and is in discussions with OrbiMed to redefine future covenants.

More on AVITA Medical

AVITA Medical: Reimbursement Reset And Breakeven Path By 2026
AVITA Medical, Inc. (RCEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
AVITA Medical: Green Shoots Peaking Out From Hard Clay
Avita Medical stock jumps 10% after securing CE Mark for RECELL GO
Avita projects $76M–$81M 2025 revenue with rebound expected as claims backlog eases

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。